A5041022383- Systemic Lupus Erythematosus Research
- Complement system in diseases
- Rheumatoid Arthritis Research and Therapies
- Renal Diseases and Glomerulopathies
- Autoimmune and Inflammatory Disorders Research
- Vasculitis and related conditions
- Skin and Cellular Biology Research
- Bone health and osteoporosis research
- Tuberculosis Research and Epidemiology
- Inflammatory Myopathies and Dermatomyositis
- Blood Coagulation and Thrombosis Mechanisms
- T-cell and B-cell Immunology
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Dermatological diseases and infestations
- Eosinophilic Disorders and Syndromes
- Tattoo and Body Piercing Complications
- Bone and Joint Diseases
- Congenital Heart Disease Studies
- Reconstructive Facial Surgery Techniques
- Multisensory perception and integration
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hair Growth and Disorders
- Liver Disease Diagnosis and Treatment
- RNA regulation and disease
- Pericarditis and Cardiac Tamponade
University of California, Irvine
2008-2024
Center for Rheumatology
2024
Centre For Human Genetics
2023
Konka (China)
2018
University of California, Irvine Medical Center
2018
New York University
2013
University School
2013
University of California, Los Angeles
2006-2011
Health First
2011
RAND Corporation
2007
To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) EULAR. This international multidisciplinary initiative included 4 phases: 1) Phase I, generation surveys literature review; 2) II, reduction modified Delphi nominal group technique exercises; 3) III, definition, further guidance real-world patient scenarios, weighting via consensus-based...
<h3>Objective</h3> To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) EULAR. <h3>Methods</h3> This international multidisciplinary initiative included four phases: (1) Phase I, generation surveys literature review; (2) II, reduction modified Delphi nominal group technique exercises; (3) III, definition, further guidance real-world patient...
The present study evaluated auditory-visual speech perception in cochlear-implant users as well normal-hearing and simulated-implant controls to delineate relative contributions of sensory experience cues. Auditory-only, visual-only, or was examined the context categorical perception, which an animated face mouthing ∕ba∕, ∕da∕, ∕ga∕ paired with synthesized phonemes from 11-token auditory continuum. A three-alternative, forced-choice method used yield percent identification scores....
Cutaneous lupus erythematosus (CLE) is a chronic inflammatory autoimmune skin disease. Evidence-based therapy for CLE lacking in the most part. Intravenous immunoglobulin (IVIg) being increasingly utilized as off-label variety of and conditions, especially dermatology. The usefulness IVIg not well established. goal present study was to obtain proof-of-concept evidence that can control acute thus replace current systemic immunosuppressive causes severe side effects adverse reactions. Sixteen...
Among the spectrum of disease manifestations associated with systemic lupus erythematosus, nephritis is particularly concerning due to potential for renal failure. This autoimmune attack may not, however, be limited kidney and increasingly being recognized as a trigger atypical Hemolytic Uremic Syndrome (aHUS). Atypical HUS falls under thrombotic microangiopathies (TMAs)–a group disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, end organ damage. Although plasma...
Systemic lupus erythematosus (SLE) can be a devastating condition, striking young patients often in their prime reproductive years. Lupus nephritis is common and serious complication occurring roughly 50% of SLE cases, indicating high likelihood disease progression, morbidity, mortality. As the early trials steroid therapy, later cyclophosphamide (CYC), therapeutic changes had been stagnant. Then came introduction mycophenolate mofetil (MMF) 2000s. After Aspreva Management Study, there...
Thrombotic microangiopathies (TMAs) involve multiple organ systems due to the presence of microangiopathic hemolysis. One such condition, atypical hemolytic uremic syndrome (aHUS), is a complement-mediated process that part spectrum disorders have underlying complement dysfunction alternative pathway overactivity or decreased self-nonself discrimination by innate immunity. Complement-amplifying conditions as pregnancy may unmask diagnosis aHUS. We present an important case pregnant...
Purpose of review The purpose this is to highlight the importance a multidisciplinary thrombotic microangiopathies (TMA) Team. This goal will be accomplished through complement system, discuss various causes (TMA), and aspects their diagnosis management. In so doing, readers gain an appreciation for complexity family disorders realize benefit dedicated TMA Recent findings derive from multiple specialty areas, are difficult timely recognize, pose complex challenges, require Hematopoietic stem...
Silicone in liquid and gel implantation may induce granuloma formation migration. Although there are many complications associated with solid silicone implantation, have been no published reports of distant formation. We present a case woman clinical serologic findings that consistent systemic lupus erythematosus histopathologic diagnosis foreign body granulomatous dermatitis 20 years after nasal implantation. review the literature on granulomas their treatment speculate potential etiologies...
Objective To investigate the availability of images representing Black, Indigenous, and people color in rheumatology educational resources. Methods Color were collected from 5 major resources cataloged by they came from, underlying rheumatic conditions, skin type. Fitzpatrick type (FST) was used to categorize into “light,” “dark,” or “indeterminate.” The initially scored a fellow Division Rheumatology subsequently validated faculty member Department Dermatology. Results Of thousands...
Infliximab and golimumab are intravenously (IV) administered tumor necrosis factor inhibitors approved to treat moderate-to-severe rheumatoid arthritis (RA) with concomitant methotrexate. Owing differences in biologic construct, patients IV-infliximab treatment failure may benefit from switching IV-golimumab. Utilizing the ACR's Rheumatology Informatics System for Effectiveness (RISE), a large electronic health records registry based USA, we assessed RA disease activity This retrospective,...